Exact Mass: 499.2101
Exact Mass Matches: 499.2101
Found 201 metabolites which its exact mass value is equals to given mass value 499.2101
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
CGS 21680
D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058913 - Purinergic Agonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
2-(4-(2-Carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine
D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058913 - Purinergic Agonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
Evodenoson
Tyr-Gly-Gly-Phe-Gly-OH
Ser His Gln Glu
Ala His Ser Trp
Ala His Trp Ser
Ala Ser His Trp
Ala Ser Trp His
Ala Trp His Ser
Ala Trp Ser His
Cys Lys Ser Tyr
Cys Lys Tyr Ser
Cys Ser Lys Tyr
Cys Ser Tyr Lys
Cys Tyr Lys Ser
Cys Tyr Ser Lys
Asp His Gln Thr
Asp His Thr Gln
Asp Gln His Thr
Asp Gln Thr His
Asp Thr His Gln
Asp Thr Gln His
Glu His Asn Thr
Glu His Gln Ser
Glu His Ser Gln
Glu His Thr Asn
Glu Asn His Thr
Glu Asn Thr His
Glu Gln His Ser
Glu Gln Ser His
Glu Ser His Gln
Glu Ser Gln His
Glu Thr His Asn
Glu Thr Asn His
Phe Gly Asn Tyr
Phe Gly Tyr Asn
Phe Asn Gly Tyr
Phe Asn Tyr Gly
Phe Tyr Gly Asn
Phe Tyr Asn Gly
Gly Phe Asn Tyr
Gly Phe Tyr Asn
Gly His Thr Trp
Gly His Trp Thr
Gly Asn Phe Tyr
Gly Asn Tyr Phe
Gly Thr His Trp
Gly Thr Trp His
Gly Trp His Thr
Gly Trp Thr His
Gly Tyr Phe Asn
Gly Tyr Asn Phe
His Ala Ser Trp
His Ala Trp Ser
His Asp Gln Thr
His Asp Thr Gln
His Glu Asn Thr
His Glu Gln Ser
His Glu Ser Gln
His Glu Thr Asn
His Gly Thr Trp
His Gly Trp Thr
His Asn Glu Thr
His Asn Thr Glu
His Gln Asp Thr
His Gln Glu Ser
His Gln Ser Glu
His Gln Thr Asp
His Ser Ala Trp
His Ser Glu Gln
His Ser Gln Glu
His Ser Trp Ala
His Thr Asp Gln
His Thr Glu Asn
His Thr Gly Trp
His Thr Asn Glu
His Thr Gln Asp
His Thr Trp Gly
His Trp Ala Ser
His Trp Gly Thr
His Trp Ser Ala
His Trp Thr Gly
Lys Cys Ser Tyr
Lys Cys Tyr Ser
Lys Ser Cys Tyr
Lys Ser Tyr Cys
Lys Tyr Cys Ser
Lys Tyr Ser Cys
Asn Glu His Thr
Asn Glu Thr His
Asn Phe Gly Tyr
Asn Phe Tyr Gly
Asn Gly Phe Tyr
Asn Gly Tyr Phe
Asn His Glu Thr
Asn His Thr Glu
Asn Thr Glu His
Asn Thr His Glu
Asn Tyr Phe Gly
Asn Tyr Gly Phe
Gln Asp His Thr
Gln Asp Thr His
Gln Glu His Ser
Gln Glu Ser His
Gln His Asp Thr
Gln His Glu Ser
Gln His Ser Glu
Gln His Thr Asp
Gln Ser Glu His
Gln Ser His Glu
Gln Thr Asp His
Gln Thr His Asp
Ser Ala His Trp
Ser Ala Trp His
Ser Cys Lys Tyr
Ser Cys Tyr Lys
Ser Glu His Gln
Ser Glu Gln His
Ser His Ala Trp
Ser His Glu Gln
Ser His Trp Ala
Ser Lys Cys Tyr
Ser Lys Tyr Cys
Ser Gln Glu His
Ser Gln His Glu
Ser Trp Ala His
Ser Trp His Ala
Ser Tyr Cys Lys
Ser Tyr Lys Cys
Thr Asp His Gln
Thr Asp Gln His
Thr Glu His Asn
Thr Glu Asn His
Thr Gly His Trp
Thr Gly Trp His
Thr His Asp Gln
Thr His Glu Asn
Thr His Gly Trp
Thr His Asn Glu
Thr His Gln Asp
Thr His Trp Gly
Thr Asn Glu His
Thr Asn His Glu
Thr Gln Asp His
Thr Gln His Asp
Thr Trp Gly His
Thr Trp His Gly
Trp Ala His Ser
Trp Ala Ser His
Trp Gly His Thr
Trp Gly Thr His
Trp His Ala Ser
Trp His Gly Thr
Trp His Ser Ala
Trp His Thr Gly
Trp Ser Ala His
Trp Ser His Ala
Trp Thr Gly His
Trp Thr His Gly
Tyr Cys Lys Ser
Tyr Cys Ser Lys
Tyr Phe Gly Asn
Tyr Phe Asn Gly
Tyr Gly Phe Asn
Tyr Gly Asn Phe
Tyr Lys Cys Ser
Tyr Lys Ser Cys
Tyr Asn Phe Gly
Tyr Asn Gly Phe
Tyr Ser Cys Lys
Tyr Ser Lys Cys
methyl 4-cyano-5-[[5-cyano-2,6-bis[(3-methoxypropyl)amino]-4-methyl-3-pyridyl]azo]-3-methyl-2-thenoate
Ranolazine dihydrochloride
C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
Evodenoson
C78283 - Agent Affecting Organs of Special Senses > C29705 - Anti-glaucoma Agent
2-acetamido-N-[(2S,4R)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-hydroxyphenyl)propanamide
N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[(1R,3S,4aR,9aS)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
N-[(1S,3S,4aR,9aS)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
3-[4-[2-[[6-amino-9-[(2R,5S)-5-(ethylcarbamoyl)-3,4-dihydroxy-2-oxolanyl]-2-purinyl]amino]ethyl]phenyl]propanoic acid
N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[(1R,3R,4aR,9aS)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]pyridine-3-carboxamide
N-[(1S,3S,4aS,9aR)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
N-[(1R,3R,4aS,9aR)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[(1R,3S,4aS,9aR)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
[3-methoxy-2-[methyl-[(E)-10,16,16-trichlorohexadec-4-enoyl]amino]propyl] acetate
3-[4-[2-[[6-Amino-9-[5-(ethylcarbamoyl)-3,4-dihydroxy-2-oxolanyl]-2-purinyl]amino]ethyl]phenyl]propanoic acid
D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058913 - Purinergic Agonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
Osteogenic Growth Peptide (10-14)
Osteogenic Growth Peptide (10-14) (OGP(10-14)), the C-terminal truncated pentapeptide of osteogenic growth peptide (OGP), retains the full OGP-like activity. Osteogenic Growth Peptide (10-14) is responsible for the binding to the OGP receptor and activates an intracellular Gi-protein-MAP kinase signaling pathway. Osteogenic Growth Peptide (10-14) is a potent mitogen and stimulator of osteogenesis and hematopoiesis. Osteogenic Growth Peptide (10-14) acts as a Src inhibitor[1][2][3][4].